NCT00140621View on ClinicalTrials.gov

A Safety and Efficacy Study of Fabrazyme® Replacement Therapy in Patients With Cardiac Fabry Disease

PHASE4CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

August 31, 2012

Study Completion Date

August 31, 2012

Conditions
Fabry Disease
Interventions
DRUG

Agalsidase beta

Trial Locations (7)

470-1192

Fujita Health University Hospital, Aichi

060-8543

Sapporo Medical University Hospital, Hokkaido

899-1611

Akune Citizen Hospital, Kagoshima

980-8574

Tohoku University Hospital, Miyagi

173-8610

Nihon University Itabashi Hospital, Tokyo

179-0072

Nihon University Nerima Hikarigaoka Hospital, Tokyo

400-8506

Yamanashi Prefectural Central Hospital, Yamanashi

All Listed Sponsors
lead

Genzyme, a Sanofi Company

INDUSTRY

NCT00140621 - A Safety and Efficacy Study of Fabrazyme® Replacement Therapy in Patients With Cardiac Fabry Disease | Biotech Hunter | Biotech Hunter